Emerging Market Outsourcing Report - Q1 2025

Emerging Market Outsourcing Report - Q1 2025

Summary

This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q1 2025, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and packaging (clinical and commercial) for countries in emerging markets.

Scope

• The current landscape of the pharmaceutical and biotechnology industries in emerging markets is marked by significant developments and emerging trends that present both challenges and opportunities for stakeholders. This 22-page report highlights key industry trends, regulatory changes, and market dynamics that are shaping the future of contract development and manufacturing organizations (CDMOs) and pharmaceutical companies for countries in emerging markets in Q1 2025. Findings are based on the industry’s most comprehensive database of the emerging markets industry (GlobalData's Contract Service Providers and Deals Databases).

This report is required reading for -

• CMO Executives and Strategic Decision-Makers: This report provides insights into emerging market trends and regulatory changes, enabling CMO executives to make informed decisions about potential partnerships and site acquisitions to enhance their competitive and global positioning.
• Sourcing and Procurement Executives at Biopharmaceutical Companies: By leveraging the findings in this report, sourcing and procurement executives can identify reliable suppliers and assess the risks associated with outsourcing in emerging markets to ensure compliance and quality in their global supply chains.
• Private Equity Investors: This report offers a comprehensive analysis of market dynamics and investment opportunities, allowing private equity investors to strategically evaluate potential acquisitions and investments in the rapidly evolving pharmaceutical and biotechnology sectors for emerging markets.

Reasons to Buy

This report will enable the user to answer the following questions -

• What impact have recent US tariffs on pharmaceuticals had on domestic manufacturing trends among major pharmaceutical companies?
• How might the imposition of tariffs affect the pricing of pharmaceuticals in the US market?
• What are the potential consequences of retaliatory tariffs from other countries on US pharmaceutical exports?
• What regulatory changes are being proposed by BRICS nations to facilitate the market for biosimilars and biologics?
• How is India's regulatory landscape evolving for pharmaceutical manufacturing, particularly for MSMEs?
• What are the latest trends in contract service agreements within the emerging markets of the pharmaceutical industry?
• What mergers and acquisitions have occurred in the pharmaceutical sector during Q1 2025, and what do they signify for the industry?
• How are global supply chains for active pharmaceutical ingredients (APIs) being affected by regulatory changes and inspections?
• What are the emerging trends in the production of biologics and biosimilars in the BRICS countries?
• What are the key challenges and opportunities for contract research, development, and manufacturing organizations (CRDMOs) in India?
• How are advancements in technology and regulatory frameworks influencing the production of mRNA vaccines and other biologics?
• What are the outcomes of FDA inspections and compliance issues for pharmaceutical manufacturers in India?